Charles River Labs stock heads into the open after a 3.0 percent jump
Published on 09/18/2026 at 05:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Charles River Labs stock closed at USD 281.70 on the New York Stock Exchange on September 17, 2026, marking a 3.0 percent gain versus the prior close per market data from a same-day session wrap. The advance left the shares trading close to a recent intraday level around USD 283.94 and outpacing a roughly 1.7 percent rise in the Nasdaq Composite on September 17, 2026 as broad United States equity benchmarks also moved higher.
September 17, 2026 in numbers
Charles River Laboratories International, Inc. (ISIN US1591881009, NYSE: CRL) saw its shares trade near USD 283.94 during the September 17, 2026 session on the NYSE, adding USD 10.53 or 3.85 percent intraday at one point according to a valuation focused overview carried by Ad-hoc-news. That report cited a prior close of USD 273.41 on September 16, 2026 and described the stock as trading close to a 52-week high band around USD 273.32 during mid-September, underscoring how the latest session left the shares only a few percent below recent peak levels.
A separate trading recap noted that the shares closed the September 17, 2026 session at USD 281.70, up 3.0 percent from the previous day and extending the recent upswing as investors responded to company specific news, according to FinancialContent. In that context the stock outperformed major indices, with the technology heavy Nasdaq Composite reported as gaining about 1.7 percent on September 17, 2026 as United States semiconductor and growth names rallied, per a separate market summary on a financial news portal that highlighted three index moves for the same date.
Rapid cell banking launch in focus today
Today investors are set to weigh the implications of Charles River Laboratories introducing rapid cell banking programs that were announced on September 17, 2026, a move aimed at shortening release timelines for biopharmaceutical and advanced therapy developers, as detailed in a company news release distributed via Financial Times Markets. The program leverages rapid and in vitro methods to reduce cell banking timelines, positioning Charles River as a partner for clients seeking faster paths from early development to clinical trial readiness, as emphasized in the same release. Alongside the technical initiative, investors may also track upcoming investor conference participation flagged in a September 17, 2026 item on StockTitan, which noted that Charles River plans to present at Morgan Stanley and Baird investor conferences in the coming days, events that can provide additional commentary on strategy and demand trends as the stock heads into today’s United States trading session.
